Associated Papers
Clinical experience of using integrated whole genome and transcriptome sequencing as a framework for pediatric and adolescent acute myeloid leukemia diagnosis and risk assessment.
Voss RK et al.
Leukemia, 2025
41057686 (PubMed )
Supplement: 41375_2025_2774_MOESM2_ESM.xlsx › S3_-_SNVs__small_INDELS
Proteomic subtypes enrich current acute myeloid leukemia nomenclature and reflect intrinsic pathogenesis alongside aging.
Cheng WY et al.
Blood, 2025
40829168 (PubMed )
Supplement: BLOOD_BLD-2024-027692-mmc5.xlsx › Sheet_1
Leveraging genomic diagnostics for prognostics and therapeutics in pediatric acute leukemia.
Newman H et al.
Hemasphere, 2025
41306327 (PubMed )
Supplement: HEM3-9-e70269-s013.xlsx › Supplemental_Table_5_-_SSVs
Persistent postremission clonal hematopoiesis shapes the relapse trajectories of acute myeloid leukemia.
Chow RD et al.
Blood Advances, 2025
39938015 (PubMed )
Supplement: BLOODA_ADV-2024-015149-mmc2.xlsx › S2
How to combine multiple tools for the genetic diagnosis work-up of pediatric B-cell acute lymphoblastic leukemia.
Hidalgo-Gómez G et al.
Annals of Hematology, 2025
39843811 (PubMed )
Supplement: 277_2024_6151_MOESM1_ESM.xlsx › S1._Genetics_data
cfDNA Chimerism and Somatic Mutation Testing in Early Prediction of Relapse After Allogeneic Stem Cell Transplantation for Myeloid Malignancies.
Rowley SD et al.
Cancers, 2025
40002220 (PubMed )
Supplement: cancers-17-00625-s001.zip › cancers-3405985-supplementary.pdf
Single-cell DNA and surface protein characterization of high hyperdiploid acute lymphoblastic leukemia at diagnosis and during treatment.
Aertgeerts M et al.
Hemasphere, 2025
39944233 (PubMed )
Supplement: HEM3-9-e70085-s003.xlsx › XF98
HLF gene is a poor prognostic factor in acute myeloid leukemia patients with FLT3-ITD/NPM1 mutations undergoing hematopoietic transplantation.
Xu X et al.
Plos One, 2025
41086161 (PubMed )
Supplement: pone.0333690.s006.xlsx › Sheet1
Early drivers of clonal hematopoiesis shape the evolutionary trajectories of de novo acute myeloid leukemia.
Chow RD et al.
Medrxiv : the Preprint Server for Health Sciences, 2024
39252918 (PubMed )
Supplement: media-1.xlsx › S1
Whole Exome Sequencing of Intermediate-Risk Acute Myeloid Leukemia without Recurrent Genetic Abnormalities Offers Deeper Insights into New Diagnostic Classifications.
Guijarro F et al.
International Journal of Molecular Sciences, 2024
39201354 (PubMed )
Supplement: ijms-25-08669-s001.zip › ijms-3087068-supplementary › Supplementary_Tables_S1-S5.xlsx › Table_S1
Non-canonical FLT3 alterations reveal novel germline FLT3 variants leading to somatic gene rescue mutations.
Gordon J et al.
Blood Cancer Journal, 2024
39080258 (PubMed )
Supplement: 41408_2024_1104_MOESM1_ESM.xlsx › Activation_Loop
Exploring the interplay between microRNA expression and DNA mutation analysis in AML patients.
Saeed RH et al.
Saudi Journal of Biological Sciences, 2024
Establishment and validation of a gene mutation-based risk model for predicting prognosis and therapy response in acute myeloid leukemia.
Liu Y et al.
Heliyon, 2024
38831838 (PubMed )
Supplement: mmc3.xlsx › Sheet1
FLT3-TKD Measurable Residual Disease Detection Using Droplet Digital PCR and Clinical Applications in Acute Myeloid Leukemia.
Li EW et al.
International Journal of Molecular Sciences, 2024
Landscape of FLT3 Variations Associated with Structural and Functional Impact on Acute Myeloid Leukemia: A Computational Study.
Mirza Z et al.
International Journal of Molecular Sciences, 2024
38542393 (PubMed )
Supplement: ijms-25-03419-s001.zip › ijms-2877317-supplementary.pdf
Characterisation of FLT3 alterations in childhood acute lymphoblastic leukaemia.
Gutierrez-Camino A et al.
British Journal of Cancer, 2024
38049555 (PubMed )
Supplement: 41416_2023_2511_MOESM1_ESM.pdf
A new genomic framework to categorize pediatric acute myeloid leukemia.
Umeda M et al.
Nature Genetics, 2024
38212634 (PubMed )
Supplement: 41588_2023_1640_MOESM5_ESM.xlsx › Extended_data_Fig.1_source_data
Next-Generation Sequencing-Based Genomic Profiling of Children with Acute Myeloid Leukemia.
Krizsán S et al.
The Journal of Molecular Diagnostics : Jmd, 2023
37088137 (PubMed )
Supplement: mmc4.xlsx › Supplementary_Table_S4
Optical Genome Mapping Identifies Novel Recurrent Structural Alterations in Childhood ETV6::RUNX1+ and High Hyperdiploid Acute Lymphoblastic Leukemia.
Brandes D et al.
Hemasphere, 2023
37469802 (PubMed )
Supplement: hs9-7-e925-s001.xlsx › Table_S12
Indole-based FLT3 inhibitors and related scaffolds as potential therapeutic agents for acute myeloid leukemia.
Ezelarab HAA et al.
Bmc Chemistry, 2023
SPINK2 Protein Expression Is an Independent Adverse Prognostic Marker in AML and Is Potentially Implicated in the Regulation of Ferroptosis and Immune Response.
Pitts HA et al.
International Journal of Molecular Sciences, 2023
37298647 (PubMed )
Supplement: ijms-24-09696-s001.zip › Manuscript_SPINK2_supplementary_tables.xlsx › Table_S14
Compartment-specific mutational landscape of clonal hematopoiesis.
Hartmann L et al.
Leukemia, 2022
36131041 (PubMed )
Supplement: 41375_2022_1700_MOESM1_ESM.pdf
Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms.
Sperling AS et al.
Blood, 2022
35512188 (PubMed )
Supplement: BLOOD_BLD-2021-014956-mmc1.pdf
Genomic landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the CALGB 10603/RATIFY trial.
Jahn N et al.
Leukemia, 2022
35922444 (PubMed )
Supplement: 41375_2022_1650_MOESM2_ESM.xlsx › NGS_dataset
Multi-omics analysis defines highly refractory RAS burdened immature subgroup of infant acute lymphoblastic leukemia.
Isobe T et al.
Nature Communications, 2022
36042201 (PubMed )
Supplement: 41467_2022_32266_MOESM11_ESM.xlsx › Data8
Monitoring of Leukemia Clones in B-cell Acute Lymphoblastic Leukemia at Diagnosis and During Treatment by Single-cell DNA Amplicon Sequencing.
Meyers S et al.
Hemasphere, 2022
Distinct genomic landscape of Chinese pediatric acute myeloid leukemia impacts clinical risk classification.
Liu T et al.
Nature Communications, 2022
35347147 (PubMed )
Supplement: 41467_2022_29336_MOESM8_ESM.xlsx › Sheet1
Analytical and clinical validation of an amplicon-based next generation sequencing assay for ultrasensitive detection of circulating tumor DNA.
Poh J et al.
Plos One, 2022
35486650 (PubMed )
Supplement: pone.0267389.s008.xlsx › S1_Table
In a multi-institutional cohort of myeloid sarcomas, NFE2 mutation prevalence is lower than previously reported.
Anekpuritanang T et al.
Blood Advances, 2021
34559205 (PubMed )
Supplement: advancesADV2021004983-suppl1.pdf
Genomes for Kids: The Scope of Pathogenic Mutations in Pediatric Cancer Revealed by Comprehensive DNA and RNA Sequencing.
Newman S et al.
Cancer Discovery, 2021
34301788 (PubMed )
Supplement: cd-20-1631_supplementary_tables_suppst1.xlsx › S2.Somatic_Findings_Summary
Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory, or High-Risk Leukemias: A Report from the LEAP Consortium.
Pikman Y et al.
Cancer Discovery, 2021
Mutation profile and immunoscore signature in thymic carcinomas: An exploratory study and review of the literature.
Asselta R et al.
Thoracic Cancer, 2021
33704917 (PubMed )
Supplement: TCA-12-1271-s003.xls › Foglio1
Performances of Targeted RNA Sequencing for the Analysis of Fusion Transcripts, Gene Mutation, and Expression in Hematological Malignancies.
Hayette S et al.
Hemasphere, 2021
33880432 (PubMed )
Supplement: hs9-5-e522-s003.pdf
Analytical validation and performance characteristics of a 48-gene next-generation sequencing panel for detecting potentially actionable genomic alterations in myeloid neoplasms.
Rosenthal SH et al.
Plos One, 2021
33909614 (PubMed )
Supplement: pone.0243683.s005.xlsx › S5A
Comprehensive Custom NGS Panel Validation for the Improvement of the Stratification of B-Acute Lymphoblastic Leukemia Patients.
Montaño A et al.
Journal of Personalized Medicine, 2020
32967112 (PubMed )
Supplement: jpm-10-00137-s001.pdf
Clinical utility of target capture-based panel sequencing in hematological malignancies: A multicenter feasibility study.
Yasuda T et al.
Cancer Science, 2020
32619037 (PubMed )
Supplement: CAS-111-3367-s004.xlsx › Sup.Table3
Deciphering the molecular mechanism of FLT3 resistance mutations.
Georgoulia PS et al.
The Febs Journal, 2020
Hybridization capture-based next generation sequencing reliably detects FLT3 mutations and classifies FLT3-internal tandem duplication allelic ratio in acute myeloid leukemia: a comparative study to standard fragment analysis.
He R et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc, 2020
Gilteritinib is a clinically active FLT3 inhibitor with broad activity against FLT3 kinase domain mutations.
Tarver TC et al.
Blood Advances, 2020
1–50 of 100 papers
Select a paper to view details